Literature DB >> 22038623

Pacing to reduce refractory angina in patients with severe coronary artery disease: a crossover pilot trial.

Craig M Stolen1, Yui-Ming Lam, Chung-Wah Siu, Chu-Pak Lau, J Anthony Parker, Thomas H Hauser, Hung-Fat Tse.   

Abstract

Biventricular pacing (BiV) has been shown to reduce wall stress and workload in regions near the pacing sites. This trial investigated if BiV near the ischemic region would reduce chest pain in patients with refractory angina due to severe coronary artery disease (CAD). Eleven patients were implanted with BiV devices with leads positioned at or adjacent to their ischemic regions as detected by single-photon emission computed tomography (SPECT) and randomized to either pacing turned ON or OFF for 3 months, and then crossed over for 3 months. With pacing turned ON, a Dynamic atrioventricular (AV) delay was set for approximately 90% and 70% of the intrinsic AV delay at the resting heart rate and at the onset of symptoms, respectively. One patient was excluded from the analysis due to a large amount of RV pacing during the OFF periods (24-64%) and due to an inability to properly deliver therapy because of an excessive number of ventricular premature complexes. Overall, with the device ON vs. OFF, the number of angina episodes (0.8 ± 0.4 vs. 1.2 ± 0.7 per week, P = 0.03) and amount of nitroglycerin used (0.2 ± 0.1 vs. 1.0 ± 0.7 per week, P = 0.11) was lower with BiV pacing. Furthermore, the treadmill exercise time to symptoms trended higher (427 ± 65 vs. 408 ± 64 s, P = 0.19), and the sum of fluorodeoxyglucose-positron emission tomography (FDG-PET) scores trended lower (7.9 ± 3.5 vs. 12.0 ± 4.0, P = 0.11) with the device ON vs. OFF. Nevertheless, there were no significant differences in SPECT myocardial perfusion scores, left ventricle ejection fraction, wall motion score index, and quality of life scores with device programmed ON vs. OFF (all P > 0.05). In conclusion, this pilot study demonstrated that BiV-P at or near the ischemic region was feasible and associated with significant reductions in angina in patients with severe CAD. Adequately powered prospective studies are needed to confirm these findings.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22038623     DOI: 10.1007/s12265-011-9326-7

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  18 in total

1.  Two-dimensional echocardiographic determination of left ventricular volume, systolic function, and mass. Summary and discussion of the 1989 recommendations of the American Society of Echocardiography.

Authors:  N B Schiller
Journal:  Circulation       Date:  1991-09       Impact factor: 29.690

2.  Recovery of regional left ventricular dysfunction after coronary revascularization. Impact of myocardial viability assessed by nuclear imaging and vessel patency at follow-up angiography.

Authors:  J vom Dahl; C Altehoefer; F H Sheehan; P Buechin; R Uebis; B J Messmer; U Buell; P Hanrath
Journal:  J Am Coll Cardiol       Date:  1996-10       Impact factor: 24.094

3.  Patients with coronary artery disease not amenable to traditional revascularization: prevalence and 3-year mortality.

Authors:  Benjamin Williams; Madhav Menon; Daniel Satran; Daniel Hayward; James S Hodges; M Nicholas Burke; Randall K Johnson; Anil K Poulose; Jay H Traverse; Timothy D Henry
Journal:  Catheter Cardiovasc Interv       Date:  2010-05-01       Impact factor: 2.692

Review 4.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

Authors:  N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger
Journal:  J Am Soc Echocardiogr       Date:  1989 Sep-Oct       Impact factor: 5.251

Review 5.  Exercise stress testing. An overview of current guidelines.

Authors:  S A Lear; A Brozic; J N Myers; A Ignaszewski
Journal:  Sports Med       Date:  1999-05       Impact factor: 11.136

6.  Peri-infarct pacing with CRT in the early postinfarct phase to attenuate long-term remodeling.

Authors:  Eugene S Chung; Wojciech Mazur; Santosh G Menon; Edward J Schloss; Theodore Chow; Dean J Kereiakes
Journal:  J Cardiovasc Transl Res       Date:  2008-09-26       Impact factor: 4.132

7.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

Authors:  Donald Lloyd-Jones; Robert Adams; Mercedes Carnethon; Giovanni De Simone; T Bruce Ferguson; Katherine Flegal; Earl Ford; Karen Furie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary McDermott; James Meigs; Dariush Mozaffarian; Graham Nichol; Christopher O'Donnell; Veronique Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Randall Stafford; Julia Steinberger; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan Wong; Judith Wylie-Rosett; Yuling Hong
Journal:  Circulation       Date:  2008-12-15       Impact factor: 29.690

8.  Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial).

Authors:  Hung-Fat Tse; Sukumaran Thambar; Yok-Lam Kwong; Philip Rowlings; Greg Bellamy; Jane McCrohon; Paul Thomas; Bruce Bastian; John K F Chan; Gladys Lo; Chi-Lai Ho; Wing-Sze Chan; Raymond Y Kwong; Anthony Parker; Thomas H Hauser; Jenny Chan; Daniel Y T Fong; Chu-Pak Lau
Journal:  Eur Heart J       Date:  2007-11-05       Impact factor: 29.983

9.  Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation.

Authors:  Hung-Fat Tse; Yok-Lam Kwong; John K F Chan; Gladys Lo; Chi-Lai Ho; Chu-Pak Lau
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321

10.  Ventricular preexcitation modulates strain and attenuates cardiac remodeling in a swine model of myocardial infarction.

Authors:  Allan C Shuros; Rodney W Salo; Viorel G Florea; Joseph Pastore; Michael A Kuskowski; Y Chandrashekhar; Inder S Anand
Journal:  Circulation       Date:  2007-08-20       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.